Merck & Co. balance sheet
At the end of fiscal 2025, Merck & Co. had total assets of $136.87bn and shareholders' equity of $52.61bn. It held $14.56bn in cash against $49.34bn of debt: net debt of $34.77bn.
Balance sheet
| Fiscal year | 2007Dec 2007 | 2008Dec 2008 | 2009Dec 2009 | 2010Dec 2010 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.3 | 4.4 | 9.3 | 10.9 | 6.5 | 6.1 | 8.0 | 9.7 | 8.1 | 8.1 | 12.7 | 6.8 | 13.2 | 14.6 | 6.8 |
| Receivables | — | 2.8 | 6.6 | 7.3 | 7.0 | 6.9 | 7.1 | 6.8 | 6.8 | 9.2 | 9.5 | 10.3 | 10.3 | 11.8 | 12.6 |
| Inventory | — | 2.1 | 8.0 | 5.9 | 4.9 | 5.1 | 5.4 | 6.0 | 5.6 | 6.0 | 5.9 | 6.4 | 6.1 | 6.7 | 6.2 |
| Total current assets | — | 19.1 | 28.4 | 29.1 | 30.6 | 24.8 | 25.9 | 27.5 | 27.8 | 30.3 | 35.7 | 32.2 | 38.8 | 43.5 | 36.7 |
| Goodwill | — | 1.4 | 12.0 | 12.4 | 18.2 | 18.3 | 18.3 | 18.1 | 18.9 | 21.3 | 21.2 | 21.2 | 21.7 | 21.6 | 21.6 |
| Total assets | — | 47.2 | 112.3 | 105.8 | 95.4 | 87.9 | 82.6 | 84.4 | 91.6 | 105.7 | 109.2 | 106.7 | 117.1 | 136.9 | 129.8 |
| Accounts payable | — | 0.6 | 2.2 | 2.3 | 2.8 | 3.1 | 3.3 | 3.7 | 4.3 | 4.6 | 4.3 | 3.9 | 4.1 | 4.4 | 3.8 |
| Total current liabilities | — | 14.3 | 15.6 | 15.6 | 17.2 | 18.6 | 22.2 | 22.2 | 27.3 | 23.9 | 24.2 | 25.7 | 28.4 | 28.3 | 27.7 |
| Short-term debt | — | 2.3 | 1.4 | 2.4 | 0.6 | 3.1 | 5.3 | 3.6 | 6.4 | 2.4 | 1.9 | 1.4 | 2.6 | 2.6 | 2.8 |
| Long-term debt | — | 3.9 | 16.1 | 15.5 | 24.3 | 21.4 | 19.8 | 22.7 | 25.4 | 30.7 | 28.7 | 33.7 | 34.5 | 46.8 | 51.1 |
| Total debt | 0.0 | 6.2 | 17.5 | 17.9 | 24.8 | 24.4 | 25.1 | 26.3 | 31.8 | 33.1 | 30.7 | 35.1 | 37.1 | 49.3 | 53.9 |
| Shareholders' equity | 20.6 | 18.8 | 59.1 | 54.4 | 40.1 | 34.3 | 26.7 | 25.9 | 25.3 | 38.2 | 46.0 | 37.6 | 46.3 | 52.6 | 41.9 |
| Net debt (negative = net cash) | −5.3 | 1.9 | 8.2 | 7.0 | 18.3 | 18.3 | 17.1 | 16.7 | 23.8 | 25.0 | 18.0 | 28.3 | 23.9 | 34.8 | 47.1 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 11.4 | 10.3 | 10.8 | 11.8 | 12.1 | 11.8 | 12.2 | 12.6 |
| Inventory | 6.2 | 6.1 | 6.2 | 6.6 | 6.4 | 6.7 | 6.5 | 6.2 |
| Total current assets | 40.4 | 38.8 | 35.5 | 37.1 | 47.6 | 43.5 | 35.0 | 36.7 |
| Goodwill | 21.7 | 21.7 | 21.7 | 21.6 | 21.6 | 21.6 | 21.6 | 21.6 |
| Total assets | 117.5 | 117.1 | 115.1 | 117.5 | 129.5 | 136.9 | 128.7 | 129.8 |
| Accounts payable | 3.6 | 4.1 | 3.8 | 3.9 | 4.1 | 4.4 | 3.9 | 3.8 |
| Total current liabilities | 29.6 | 28.4 | 25.2 | 26.0 | 28.6 | 28.3 | 26.9 | 27.7 |
| Short-term debt | 3.1 | 2.6 | 1.4 | 1.4 | 1.4 | 2.6 | 2.4 | 2.8 |
| Long-term debt | 35.0 | 34.5 | 33.5 | 34.0 | 40.0 | 46.8 | 46.7 | 51.1 |
| Total debt | 38.1 | 37.1 | 34.8 | 35.4 | 41.4 | 49.3 | 49.1 | 53.9 |
| Shareholders' equity | 44.5 | 46.3 | 48.3 | 49.0 | 51.9 | 52.6 | 45.9 | 41.9 |
Compare with peers
- Pfizer balance sheet
- Astrazeneca PLC balance sheet
- Lilly (Eli) balance sheet
- Bristol Myers Squibb balance sheet
- Novo Nordisk A S balance sheet
Head to head: MRK vs PFEAZN vs MRKLLY vs MRK
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies